首页> 外国专利> Optimized cardiac contraction through differential phosphorylation of myosin

Optimized cardiac contraction through differential phosphorylation of myosin

机译:通过肌球蛋白的差异磷酸化优化心脏收缩

摘要

The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.
机译:本公开提供了肌球蛋白轻链激酶(cMLCK)的人心脏同工型的cDNA,蛋白质序列和基因组结构,并描述了与心脏功能障碍有关的cMLCK基因中的突变。提供了用于鉴定可以在cMLCK基因中包含突变或携带可能使他们易患心脏功能障碍的等位基因的个体的方法。还公开了cMLCK在调节心脏收缩性中的重要作用。本文显示了cMLCK蛋白可减少拉伸激活的幅度并增加张力产生,这是迄今为止在心脏收缩中尚未发挥作用的肌肉特性。此外,cMLCK蛋白显示在心脏中局部分布,因此对收缩性和拉伸激活具有不同的作用。提供本文中的方法以利用cMLCK的这种作用,以治疗患有或倾向于心脏功能障碍的个体。另外,提供了鉴定调节cMLCK活性的试剂的方法,从而在心脏功能障碍的治疗中具有潜在的治疗重要性。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号